Johnson & Johnson (NYSE: JNJ) has spent several quarters working toward sharpening its focus on its innovative medicine and medical technology (MedTech) businesses. It took a huge step forward by completing the spin-off of its former consumer healthcare business, Kenvue (NYSE: KVUE), to shareholders during the third quarter. With Kenvue's separation complete, Johnson & Jonhson can put its full attention behind its remaining businesses.

That strategy is already paying dividends for investors. The healthcare behemoth produced strong financial results during Q3 and raised its full-year guidance. Here's a look at the period and what's ahead for the healthcare company.

Here's a snapshot of Johnson & Johnson's income statement for the third quarter:

Continue reading

Source Fool.com